Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.70 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8353969 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL75573 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL7595982 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL4620374 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL8359972 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL277384 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL529785 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL11963130 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL57043 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 | |
| SCHEMBL11963540 | 1.00 | CA2 (0.70) | CA2FAAHCA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| CN-119219809-A | Fluorine-containing polymer, preparation method thereof and ion exchange membrane | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118185612-A | Gemini surfactant-based oil and gas field fracturing cleanup additive as well as preparation method and application thereof | 成都理工大学 | 2024-06-14 | — | — | CN | disclosed |
| EP-3395583-B1 | HEAT-SENSITIVE RECORDING MATERIAL | NIPPON KAYAKU KK (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-107209146-B | Electrochemical gas sensor and electrolyte for electrochemical gas sensor | 德尔格安全股份两合公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| US-4374036-A | TETRAPOTASSIUM PYROPHOSPHATE, SODIUM PHOSPHATE, POLYETHYLENE GLYCOL, SODIUM CARBOXYMETHYL CELLULOSE, ANTIFOAM AGENT AND POLYSILOXANE | Canale, Michael A. (US) | 1983-02-15 | — | — | US | disclosed |
| EP-0063854-A1 | Polyether thickeners for aqueous systems containing additives for increased thickening efficiency | BASF WYANDOTTE CORPORATION (US) | 1982-11-03 | — | — | EP | disclosed |
| EP-0061823-A1 | Synergistically thickened water-based hydraulic or metal-working fluid | BASF WYANDOTTE CORPORATION (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4151099-A | POLYETHOXYLATED ESTER, SULFURIZED MOLYBDENUM OR ANTIMONY ORGANOPHOSPHORODITHIOATE | BASF WYANDOTTE CORPORATION (US) | 1979-04-24 | — | — | US | disclosed |
| US-4138346-A | ETHOXYLATED PHOSPHATE ESTER WITH A MERCAPTOTHIAZOLE, A DITHIOBIS-THIAZOLE, A SULFIDE, A DISULFIDE OR A SULFONE | BASF WYANDOTTE CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
| US-3996149-A | SILICA | BURKE OLIVER W JUN | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | CA2 2765/4885FAAH 2699/4885CA1 902/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | CA2 2765/4885FAAH 2699/4885CA1 902/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | CA2 2765/4885FAAH 2699/4885CA1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.